Dramatic response to tarlatamab in a patient with metastatic primary small cell neuroendocrine carcinoma of the breast

#4569

Introduction: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a rare malignancy with a poor prognosis. Tarlatamab, a DLL3-targeted bispecific T-cell engager, is FDA-approved for extensive-stage small cell lung carcinoma.

Aim(s): This report highlights the efficacy of tarlatamab in metastatic SCNCB.

Materials and methods: Case report

Conference:

Presenting Author: Patel D

Authors: Patel D, Alahmadi A, Maddocks K, Lampert B, Giglio P,

Keywords: tarlatamab, small cell neuroendocrine carcinoma of the breast,